116 related articles for article (PubMed ID: 28637616)
1. Down syndrome, RASopathies, and other rare syndromes.
Kratz CP; Izraeli S
Semin Hematol; 2017 Apr; 54(2):123-128. PubMed ID: 28637616
[TBL] [Abstract][Full Text] [Related]
2. Predispositions to Leukemia in Down Syndrome and Other Hereditary Disorders.
Saida S
Curr Treat Options Oncol; 2017 Jul; 18(7):41. PubMed ID: 28580501
[TBL] [Abstract][Full Text] [Related]
3. PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia.
Yamamoto T; Isomura M; Xu Y; Liang J; Yagasaki H; Kamachi Y; Kudo K; Kiyoi H; Naoe T; Kojma S
Leuk Res; 2006 Sep; 30(9):1085-9. PubMed ID: 16533526
[TBL] [Abstract][Full Text] [Related]
4. Trisomy of chromosome 21 in leukemogenesis.
Izraeli S; Rainis L; Hertzberg L; Smooha G; Birger Y
Blood Cells Mol Dis; 2007; 39(2):156-9. PubMed ID: 17532652
[TBL] [Abstract][Full Text] [Related]
5. RAS diseases in children.
Niemeyer CM
Haematologica; 2014 Nov; 99(11):1653-62. PubMed ID: 25420281
[TBL] [Abstract][Full Text] [Related]
6. [Genetic predisposition to pediatric myeloid malignancies].
Muramatsu H
Rinsho Ketsueki; 2016 Jun; 57(6):730-5. PubMed ID: 27384852
[TBL] [Abstract][Full Text] [Related]
7. [Rasopathies: developmental disorders that predispose to cancer and skin manifestations].
Hernández-Martín A; Torrelo A
Actas Dermosifiliogr; 2011; 102(6):402-16. PubMed ID: 21536246
[TBL] [Abstract][Full Text] [Related]
8. Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia.
Laurent AP; Siret A; Ignacimouttou C; Panchal K; Diop M; Jenni S; Tsai YC; Roos-Weil D; Aid Z; Prade N; Lagarde S; Plassard D; Pierron G; Daudigeos E; Lecluse Y; Droin N; Bornhauser BC; Cheung LC; Crispino JD; Gaudry M; Bernard OA; Macintyre E; Barin Bonnigal C; Kotecha RS; Geoerger B; Ballerini P; Bourquin JP; Delabesse E; Mercher T; Malinge S
Clin Cancer Res; 2020 Jul; 26(13):3307-3318. PubMed ID: 32220889
[TBL] [Abstract][Full Text] [Related]
9. Evolution of myeloid leukemia in children with Down syndrome.
Saida S
Int J Hematol; 2016 Apr; 103(4):365-72. PubMed ID: 26910243
[TBL] [Abstract][Full Text] [Related]
10. Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis.
Seif AE
Cancer Genet; 2011 May; 204(5):227-44. PubMed ID: 21665176
[TBL] [Abstract][Full Text] [Related]
11. Acute lymphoblastic leukemia in the context of RASopathies.
Cavé H; Caye A; Strullu M; Aladjidi N; Vignal C; Ferster A; Méchinaud F; Domenech C; Pierri F; Contet A; Cacheux V; Irving J; Kratz C; Clavel J; Verloes A
Eur J Med Genet; 2016 Mar; 59(3):173-8. PubMed ID: 26855057
[TBL] [Abstract][Full Text] [Related]
12. Down Syndrome and acute leukaemia: increased risk may be due to trisomy 21.
Rowley JD
Lancet; 1981 Nov; 2(8254):1020-2. PubMed ID: 6118480
[No Abstract] [Full Text] [Related]
13. Modeling RASopathies with Genetically Modified Mouse Models.
Hernández-Porras I; Guerra C
Methods Mol Biol; 2017; 1487():379-408. PubMed ID: 27924582
[TBL] [Abstract][Full Text] [Related]
14. Down syndrome and leukemia--an overview of cytogenetic and molecular events.
Savaşan S; Taub JW; Ravindranath Y
Turk J Pediatr; 1997; 39(4):519-31. PubMed ID: 9433155
[No Abstract] [Full Text] [Related]
15. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes.
Kratz CP; Franke L; Peters H; Kohlschmidt N; Kazmierczak B; Finckh U; Bier A; Eichhorn B; Blank C; Kraus C; Kohlhase J; Pauli S; Wildhardt G; Kutsche K; Auber B; Christmann A; Bachmann N; Mitter D; Cremer FW; Mayer K; Daumer-Haas C; Nevinny-Stickel-Hinzpeter C; Oeffner F; Schlüter G; Gencik M; Überlacker B; Lissewski C; Schanze I; Greene MH; Spix C; Zenker M
Br J Cancer; 2015 Apr; 112(8):1392-7. PubMed ID: 25742478
[TBL] [Abstract][Full Text] [Related]
16. Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
Rauen KA; Schoyer L; Schill L; Stronach B; Albeck J; Andresen BS; Cavé H; Ellis M; Fruchtman SM; Gelb BD; Gibson CC; Gripp K; Hefner E; Huang WYC; Itkin M; Kerr B; Linardic CM; McMahon M; Oberlander B; Perlstein E; Ratner N; Rogers L; Schenck A; Shankar S; Shvartsman S; Stevenson DA; Stites EC; Stork PJS; Sun C; Therrien M; Ullian EM; Widemann BC; Yeh E; Zampino G; Zenker M; Timmer W; McCormick F
Am J Med Genet A; 2018 Dec; 176(12):2924-2929. PubMed ID: 30302932
[TBL] [Abstract][Full Text] [Related]
17. Complexity of chromosomal rearrangements in Down syndrome leukemia.
Ganguly BB; Kadam NN; Mandal PK
J Cancer Res Ther; 2017; 13(2):381-383. PubMed ID: 28643766
[TBL] [Abstract][Full Text] [Related]
18. A comparison of acute lymphoblastic leukemia in Down syndrome and non-Down syndrome children: the role of trisomy 21.
Tigay JH
J Pediatr Oncol Nurs; 2009; 26(6):362-8. PubMed ID: 20032297
[TBL] [Abstract][Full Text] [Related]
19. Trisomy 21 leukemias: finding the hits that matter.
Rabson AB
Oncogene; 2010 Nov; 29(46):6099-101. PubMed ID: 20711238
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood cells from children with RASopathies show enhanced spontaneous colonies growth in vitro and hyperactive RAS signaling.
Gaipa G; Bugarin C; Cianci P; Sarno J; Bonaccorso P; Biondi A; Selicorni A
Blood Cancer J; 2015 Jul; 5(7):e324. PubMed ID: 26186557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
